CoChat
Sign Up
Cited by 342Thyroid Cancer Diagnosis and TreatmentThyroid and Parathyroid SurgeryRenal cell carcinoma treatment

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer

Schlumberger, Martin J., Elisei, Rossella, Bastholt, Lars, Wirth, Lori J., Martins, Renato G., Locati, Laura D., Jarzab, Barbara, Pacini, Furio, Daumerie, Chantal, Droz, Jean-Pierre, Eschenberg, Michael J., Sun, Yu-Nien, Juan, Todd, Stepan, Daniel E., Sherman, Steven I.·2009·Journal of Clinical Oncology
DOI 10.1200/jco.2008.18.7815
Open this paper in CoChat — free account

Abstract

Purpose: This phase II study investigated the efficacy and tolerability of motesanib, an investigational, highly selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit in advanced medullary thyroid cancer (MTC). Patients and Methods: Patients with locally advanced or metastatic, progressive or symptomatic MTC received motesanib 125 mg/d orally for up to 48 weeks or until unacceptable toxicity or disease progression. The primary end point was objective response by independent review. Other end points included duration of response, progression-free survival, safety, pharmacokinetics, and changes in tumor markers. Results: Of 91 enrolled patients who received motesanib, two (2%) achieved objective response (95% CI, 0.3% to 7.7%); their duration of response was 32 weeks (censored) and 21 weeks (disease progressed). Eighty-one percent of patients had stable disease (48% had durable stable disease ≥ 24 weeks), 8% had disease progression as best response, and 9% were not evaluated; 76% experienced a decrease from baseline in target lesion measurement. Median progression-free survival was 48 weeks (95% CI, 43 to 56 weeks). Among patients with tumor marker analysis, 69 (83%) of 83 and 63 (75%) of 84 had decreased serum calcitonin and carcinoembryonic antigen during treatment, respectively, compared with baseline. The most common treatment-related adverse events were diarrhea (41%), fatigue (41%), hypothyroidism (29%), hypertension (27%), and anorexia (27%). In pharmacokinetic analyses, motesanib trough concentrations were lower compared with differentiated thyroid cancer patients from the same study. Conclusion: Although the objective response rate was low, a significant proportion of MTC patients (81%) achieved stable disease while receiving motesanib.

Overview

Integrity signals

Registry

Crossref · 10.1200/jco.2008.18.7815

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 35 references

Research works printed but not linked: 3

  1. Coxon A, 2007, Proc Am Assoc Cancer Res, 48, 71
  2. Baudin E, 2007, Horm Res, 68, 28
  3. Tsai MS, 1994, J Clin Endocrinol Metab, 78, 1261

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Schlumberger, M. J., Elisei, R., Bastholt, L., Wirth, L. J., Martins, R. G., Locati, L. D., Jarzab, B., Pacini, F., Daumerie, C., Droz, J.-P., Eschenberg, M. J., Sun, Y.-N., Juan, T., Stepan, D. E., & Sherman, S. I.
Affiliations
  • University of Siena (IT)
  • From the Institut Gustave Roussy, University Paris Sud, Villejuif; Centre Léon Bérard, Lyon, France; University of Pisa, Pisa; Istituto Nazionale dei Tumori, Milan; University of Siena, Siena, Italy; Odense University Hospital, Odense, Denmark; Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Université Catholique de Louvain, Brussels, Belgium; Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, MA; University of Washington, Seattle, WA; Amgen, Thousand...
ORCID
Venue
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Published
2009-08-10
Volume
27
Issue
23
Pages
3794-3801
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
DOI
10.1200/jco.2008.18.7815
OpenAlex
W2112475888
Cited by
340
References
35
Citations by year
2025: 3 · 2024: 2 · 2023: 6 · 2022: 8 · 2021: 10 · 2020: 14 · 2019: 12 · 2018: 11 · 2017: 14 · 2016: 22 · 2015: 26 · 2014: 38 · 2013: 36 · 2012: 46
FWCI
33.64
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
  • Digital Access to Libraries (submittedVersion)
  • Use Siena air (University of Siena) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
  • Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Keywords
motesanib, medullary thyroid carcinoma, metastatic thyroid cancer, VEGFR inhibitors, platelet-derived growth factor receptor, KIT inhibitors, tyrosine kinase inhibitors, progression-free survival, stable disease, calcitonin, carcinoembryonic antigen, pharmacokinetics, adverse events, diarrhea, hypothyroidism
MeSH terms
Adult, Aged, Antineoplastic Agents, Female, Humans, Indoles, Male, Middle Aged, Niacinamide, Oligonucleotides, Thyroid Neoplasms, Treatment Outcome, Receptors, Platelet-Derived Growth Factor, Carcinoma, Medullary, Proto-Oncogene Proteins c-kit, Receptors, Vascular Endothelial Growth Factor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review